Objective: Phosphodiesterase 10A (PDE10A) is an enzyme present in striatal medium spiny neurons that degrades the intracellular second messengers triggered by dopamine signaling. The pharmaceutical industry has considerable interest in PDE10A inhibitors because they have been shown to have an antipsychotic-like effect in animal models. However, the status of PDE10A in schizophrenia is unknown. Using a newly developed and validated radioligand, [
BP ND between schizophrenia patients and comparison subjects in any of the brain regions studied (thalamus, caudate, putamen, nucleus accumbens, globus pallidus, and substantia nigra). There was also no significant correlation between [ 11 C]IMA107 BP ND and the severity of psychotic symptoms or antipsychotic dosage.
Conclusions:
Patients with schizophrenia have normal availability of PDE10A in brain regions thought to be involved in the pathophysiology of this disorder. The findings do not support the proposal of an altered PDE10A availability in schizophrenia. The implication of this finding for future drug development is discussed. Schizophrenia is a chronic and disabling psychiatric illness, and despite extensive research, its molecular etiology remains unknown (1, 2) . The current dopamine hypothesis postulates that excessive striatal dopamine transmission and reduced frontal dopamine stimulation underlie the pathophysiology of positive and negative symptoms, respectively (3, 4) . All currently approved treatments (antipsychotic medications) are primarily antagonists at dopamine D 2 receptors (5-7), and because they do little to enhance frontal dopamine transmission, they have limited effect against negative and cognitive symptoms. Therefore, the field is increasingly looking beyond the dopamine system to identify new targets and medications that improve both positive and negative symptoms (8) . A promising strategy to modulate dopamine transmission without blocking D 2 receptors is by acting at a postsynaptic receptor target, such as the phosphodiesterase (PDE) enzymes.
PDEs are a class of enzymes that degrade the intracellular second messengers cAMP and cGMP, which are triggered by receptor stimulation. The PDE10A enzyme is found in neurons expressing dopamine D 1 and D 2 receptors, thereby providing cellular and functional specificity for the dopamine system (9, 10) . The inhibition of PDE10A in the medium spiny neurons of the striatum enhances functional output of the direct striatonigral pathway, functionally enhancing dopamine D 1 -related transmission, and it constrains the functional output of the indirect striatopallidal pathway by inhibiting D 2 neurotransmission (11) . Thus, in theory, PDE10A inhibitors may provide an ideal antipsychotic effect by reducing positive symptoms (via D 2 -antagonism-like effects) while simultaneously improving negative and cognitive symptoms (via enhancing D 1 -dependent neurotransmission) (see Figure S1 in the data supplement that accompanies the online edition of this article).
This notion is consistent with preclinical data demonstrating antipsychotic-like activity of PDE10A antagonists. Inhibition of PDE10A by papaverine and by more recent selective PDE10A inhibitors, such as TP-10 and MP-10, constrains psychostimulant-induced hyperactivity, constrains conditioned avoidance response, and shows positive results in several known animal models of positive symptoms in schizophrenia (10) (11) (12) (13) (14) . Because PDE10A inhibitors augment ajp in Advance ajp.psychiatryonline.org 1 D 1 -related signaling via the direct pathway, there has been considerable interest in their effect on cognitive and negative symptoms of schizophrenia, with PDE10A inhibitors showing a reversal of memory deficits induced by N-methyl-D-aspartate receptor antagonists such as phencyclidine, dizocilpine, and ketamine in rats and nonhuman primates (15) (16) (17) . This preclinical evidence has encouraged nearly 20 pharmaceutical companies to publish patent applications for PDE10A inhibitors, and five of these companies have reported clinical development of PDE10A inhibitors for the treatment of schizophrenia (18) . Nonetheless, despite the biological relevance, preclinical evidence, and extensive investment from the drug companies, very little is known about PDE10A availability in patients with schizophrenia because of the absence of a suitable PET tracer for imaging of these receptors in the living human brain. Also, no study to our knowledge has investigated the availability of PDE10A in postmortem schizophrenia brain.
We recently developed a selective PET radiotracer ([ 11 C]IMA107) and used it to image the PDE10A system in healthy comparison subjects, allowing robust quantification of PDE10A availability and the suitability of a simplified reference tissue model (19) . In this study, we report the first investigation of PDE10A availability in patients with schizophrenia using [ 
METHOD

Participants
The study protocol was approved by the National Research Ethics Service, and permission to administer radioactive substances was granted by the U.K. Administration of Radioactive Substances Advisory Committee. All participants gave written informed consent to participate after receiving a full description of the study.
Patients with schizophrenia were recruited from the South London and Maudsley Foundation National Health Service Trust. Healthy comparison subjects were recruited from the same catchment area; they were assessed with the Psychosis Screening Questionnaire (20) and were excluded if they reported any psychotic symptom or a history of psychotic illness.
All subjects had a physical, psychiatric, and neurological examination. Drug screening tests were done on the days of the scans to identify the use of psychoactive drugs. Exclusion criteria included use of psychoactive drugs; a history of head trauma or injury with loss of consciousness longer than 1 hour; organic psychosis; learning disabilities; lack of English fluency; treatment with clozapine; consuming more than 500 mg/day of caffeine; and a history of substance abuse or dependence. None of the participants had a history of other neurological or psychiatric disorders other than schizophrenia in the patient group, and none were receiving treatment with substances with known actions on PDEs.
Clinical Assessment
All patients met DSM-IV criteria for schizophrenia, paranoid subtype, as determined by a review of their medical notes using the Operational Criteria Checklist for Psychotic Illness and Affective Illness (21) .
None of the patients had experienced a symptomatic relapse, and all were on a stable dosage of an antipsychotic medication for at least 4 weeks prior to the screening visit. Three patients were taking first-generation antipsychotics (one each was taking flupentixol, pipotiazine, and fluphenazine), and the remaining nine patients were taking secondgeneration antipsychotics (four were taking risperidone, three were taking aripiprazole, and one each was taking amisulpride and paliperidone). Antipsychotic dosages were converted to chlorpromazine equivalents (22, 23) . Clinical measures recorded at the PET scan included a physical examination, urine drug screen, medication history, and measurements of antipsychotic blood levels. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS) (24) .
Image Acquisition MRI and PET imaging were performed at Imanova in London. Participants were instructed to refrain from ingesting caffeine, tobacco, and alcohol for at least 12 hours before scanning. All participants were scanned on a Siemens , and a transaxial Gaussian filter of 5 mm. MRI scans were acquired with a 32-channel head coil on a Siemens Magnetom Verio 3-T scanner and included a T 1 -weighted magnetization prepared rapid gradient echo sequence (time repetition=2300 ms, time echo=2.98 ms, flip angle=9°, time to inversion=900 ms, matrix=2403256) for coregistration with the PET images; fast GM T 1 inversion recovery (time repetition=3000 ms, time echo=2.96 ms, flip angle=8°, time to inversion=409 ms, matrix=2403256); and fluid and white matter suppression (time repetition=5000 ms, time echo=2.94 ms, flip angle=5°, time to inversion=409/1100 ms, matrix=2403256) sequences for improving delineation of subcortical brain regions. All sequences used a 1-mm 3 voxel size,
anteroposterior phase encoding direction, and a symmetric echo. Data analysis. Data were analyzed using Imanova's in-house MIAKAT software package (version 3.3.8). MIAKAT is implemented using MATLAB (version R2008b; The MathWorks, Inc., Natick, Mass.), and it makes use of the FMRIB Software Library (version 4.1.9; http://www.fmrib.ox.ac.uk/fsl/) (25, 26) functions for brain extraction and of SPM5 (http://www.fil.ion.ucl.ac.uk/spm) for image segmentation and registration. MIAKAT implements a robust and consistent analysis pipeline with built-in audit trail and prespecified quality-control points whereby the analyst is required to inspect results of intermediate stages (e.g., checking the success of automated brain extraction or assessing the quality of model fits).
Image processing and definition of regions of interest. Each subject's structural MRI image underwent brain extraction and gray matter segmentation, and it was coregistered to a standard reference space (MNI152) (27) . The MNI152 template brain image and associated atlas (CIC atlas) (28) were The regions of interest defined in this manner were the dorsal caudate, dorsal putamen, nucleus accumbens, globus pallidus, thalamus, and cerebellum. In addition, the substantia nigra was manually delineated by reference to both fluid and white matter suppression and PET summed images using Analyze, version 4 (Mayo Foundation).
Dynamic PET images were registered to each subject's MRI scan and corrected for motion using a frame-to-frame registration process with a normalized mutual information cost function. Regions of interest were applied to the dynamic PET data to derive regional time-activity curves.
Kinetic modeling. We recently demonstrated the suitability of the cerebellum as a reference region for determining the regional estimation of [ 11 C]IMA107 BP ND (19) . Therefore, regional time-activity curve data extracted from the PET images were fitted to the simplified reference tissue model (29) . The simplified reference tissue model assumes a reference region (here, the cerebellum) that is similar to the target-rich regions, except that it is devoid of the target receptor. The basis function implementation of the simplified reference tissue model employed here (30) directly estimates the binding potential relative to the nondisplaceable component (BP ND ), which can be thought of as a measure of specific binding (31) . The simplified reference tissue model was also used to generate parametric images, again using a basis function method implemented in MIAKAT.
Statistical Analysis
Statistical analysis was performed with SPSS, version 20 (IBM, Armonk, N.Y.). For all variables, variance homogeneity and normal distribution were tested with KolmogorovSmirnov tests, and we proceeded with parametric tests because our PET and clinical data were normally distributed. To determine whether there was an effect of group on BP ND values and on sociodemographic and clinical data, analysis of variance and independent t tests were performed where appropriate. We interrogated correlations between PET and clinical data using Pearson's r. All data are presented as means and standard deviations, and the alpha level was set for all comparisons at a corrected p threshold of 0.05.
RESULTS
Twelve individuals with schizophrenia and 12 healthy comparison subjects were studied. The participants' demographic and clinical characteristics are summarized in Table 1 . All patients were on an antipsychotic medication at the time of the scan, and antipsychotic blood levels were within the normal range with reference to standardized laboratory values. Psychotic symptoms were evaluated using the PANSS (mean=61.5, SD=9.7). No between-group significant differences were observed in age, gender, ethnicity, weight, or radiation dose received. There were also no significant differences between groups in nicotine or caffeine intake.
We found no significant differences in [ in the caudate (21%), putamen (6%), globus pallidus (2%), thalamus (8%), nucleus accumbens (22%), and substantia nigra (26%) compared with the healthy comparison subjects ( Figure 1 ; Table 2 ).
Correlations Between PDE-10A Availability and Clinical Characteristics No significant correlation was found between [ 11 C]IMA107 BP ND and severity of psychotic symptoms, as assessed by the PANSS, in any region (Figure 2) .
We also found no significant correlation between [ 11 C]IMA107 BP ND and exposure to antipsychotics, as measured in chlorpromazine equivalents, in any region (Figure 3 ).
DISCUSSION
To our knowledge, this is the first PET study to investigate the status of PDE10A in the brains of individuals with schizophrenia. We found no differences between patients and healthy comparison subjects and no association between PDE10A availability and clinical variables or medication exposure.
Before we discuss the implications of this finding, we should address the potential limitations of this study. Nevertheless, it has demonstrated specific binding to the PDE10A enzyme, both in animal studies and in healthy volunteers (19) . Furthermore, its high signal-to-noise ratio, reversible kinetics, and good brain penetration suggest that [ 11 C]IMA107 has optimal properties to assess PDE10 availability (19) . A potential limitation is the risk of a type II error because the relatively small sample size may not have provided adequate power to detect significant group differences. However, a post hoc power analysis shows that we had over 95% power to detect a 25% difference in PDE10A availability between groups, using the mean and variability of [ 11 C]IMA107 BP ND from our data. Although smaller differences between groups (i.e., less than 10%) cannot be rejected with our sample size, the clinical significance and implications of a smaller difference may be biologically questionable. Furthermore, some areas of the striatum, such as the caudate and the globus pallidus, showed a difference in PDE10A availability of less than 3% between groups, supporting our conclusion that availability is similar between the patients and the healthy comparison subjects. Finally, the prolonged exposure to antipsychotics in our patient sample could affect [ 11 C]IMA107 binding. Because the PDE10A system acts downstream of the dopamine D 2 receptors, it is possible that chronic D 2 receptor blockage could alter PDE levels in the brain. Dlaboga et al. (32) reported that chronic treatment with haloperidol and clozapine increases striatal PDE10A protein expression in rats, suggesting that the upregulation of PDE10A may also occur as a compensatory response to the effect of current treatments on cyclic nucleotide signaling. However, Dlaboga et al. did not measure enzyme levels using a binding marker; therefore, we inhibitor with good brain penetration and regional binding, combined with ex vivo tissue analysis for mRNA, protein levels, and enzyme activity. In that study, after 3 weeks of chronic haloperidol treatment in rodents, the PET imaging results showed no evidence of PDE10A enzyme elevation in the whole rodent striatum. Thus, as that study used the technique most comparable to our human PET data, it seems unlikely that antipsychotic use confounded the results. Investigating first-episode patients prior to the start of antipsychotic treatment could provide an unambiguous picture. These results should also be discussed in the context of previous preclinical and human data. As a relatively newly characterized protein, PDE10A has not been part of any extensive human postmortem analysis of its potential role in schizophrenia. There are no preclinical studies showing a change in PDE10A availability in animal models of schizophrenia. The majority of the studies conducted so far have repeatedly demonstrated that PDE10A inhibitors produce behavioral effects predictive of antipsychotic activity, similar to D 2 antagonists (10, 12, 13, (34) (35) (36) . Thus, while our results cannot contradict the animal findings, they do not provide any support for PDE10A-based antipsychotics. These findings are then of interest in light of a recently completed trial of the first PDE10 inhibitor (MP-10) in schizophrenia (ClinicalTrials.gov identifier: NCT01175135). In this 4-week trial, MP-10 failed to differentiate from placebo in subjects with an acute exacerbation of schizophrenia. Our results complement these findings by indicating that there is no major alteration in PDE10A in schizophrenia.
However, it is important that our findings not be interpreted as a case against developing PDE10A drugs in schizophrenia. As we noted in the introduction, the study of intracellular signaling pathways makes a persuasive case for how PDE10A inhibitors, regardless of whether there is an intrinsic change in PDE10 in schizophrenia, could influence the overall signaling in a therapeutic direction. In fact, dopamine D 2 blocking drugs have been effective antipsychotics with limited, if any, support for an intrinsic increase in the levels of dopamine D 2 receptors (7). Similarly, selective serotonin reuptake inhibitors are effective treatments in depression without a primary pathology in these transporters. That said, those pursuing PDE10A in schizophrenia will have to do so knowing that it is at best a compensatory pathway, rather than a pathological mediator.
In conclusion, this work provides evidence that patients with schizophrenia have normal availability of PDE10A in brain regions thought to be involved in the pathophysiology of this disorder. The findings of this study provide critical information for the ongoing therapeutic developments for schizophrenia.
